Princeton-based Amicus has a gene therapy research center in Philadelphia. The transaction didn't come together until after ...

FOLD, MU and AMGN delivered sharp gains as Zacks strategies beat key benchmarks despite tariff fears, policy uncertainty and ...

The latest update to the Amicus Therapeutics stock story centers on a revised price target. However, with no prior target disclosed, the focus now shifts to what this new figure may signal about ...

Hey everyone! Those of you who’ve been around ARA for a minute know that, at heart, I’m a big ERISA nerd. I mean, I go on an annual vacation with friends who work in retirement, and we talk about the ...

The termination of the merger with the special purpose acquisition company, ARYA Sciences Acquisition Corp IV, means that Amicus now needs to save $400 million—the same amount that the gene therapy ...

California-based free market think tank the Pacific Research Institute announced today that it has filed an amicus curiae brief urging the U.S. Supreme Court to hear two cases challenging the federal ...

Sixteen amicus briefs have been filed with the U.S. Supreme Court in support of the position of the Community Financial Services Association of America (CFSA) that the Court should affirm the Fifth ...

Rare disease has always been Amicus Therapeutics’ focus, but in recent years the company adjusted how it aimed to treat such disorders, a shift that followed a $100 million acquisition of a gene ...